Despite the market volatility, shares in Acacia Pharma (EBR:ACPH) have been in an uptrend in recent months. The question now for investors is whether that price strength will continue. Finding stocks with the potential to break-out as...
ACPH — Acacia Pharma Share Price
0.000.00%
Last Trade - 00:00HealthcareHighly SpeculativeSmall CapSucker Stock
- €219.87m
- €211.33m
- €0.21m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | n/a | n/a | n/a | n/a | 0.21 | 7.03 | 41.25 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
12345678910
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Latest News & Insights for ACPH
Despite the market volatility, shares in Acacia Pharma (EBR:ACPH) have been in an uptrend in recent months. The question now for investors is whether that price strength will continue. Finding stocks with the potential to break-out as...
Profile Summary
Acacia Pharma Group PLC is a United Kingdom-based company specialized in the pharmaceutical industry. The pharmaceutical group focuses on the development and commercialization of new nausea and vomiting treatments for surgical and cancer patients. Its pipeline includes BAREMIS, an intravenous formulation of amisulpride, which is a selective dopamine antagonist that has completed phase 3 clinical development for the prophylaxis and treatment of Postoperative nausea and vomiting (PONV), and APD403, which is based on the selective dopamine antagonist amisulpride and it is being developed as an intravenous injection for cancer patients to be administered immediately before chemotherapy to prevent acute chemotherapy-induced nausea & vomiting ( CINV).
Directors
- Michael Bolinder CEO
- Gary Gemignani (54)
- Gabriel Fox
- Debra Hussain
- Anne-Marie Elsley
- Scott Byrd
- Edward Borkowski (61)
- John Brown (64)
- Last Annual
- December 31st, 2020
- Last Interim
- December 31st, 2020
- Incorporated
- September 2nd, 2015
- Public Since
- March 5th, 2018
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Euronext - Brussels
- Shares in Issue
- 99,713,951
- Address
- The Officers Mess Business Centre, CAMBRIDGE, CB22 4QH
- Web
- http://acaciapharma.com/
- Phone
- +44 1223919760
- Contact
- Gary Gemignani
- Auditors
- PricewaterhouseCoopers LLP
Latest News for ACPH
Upcoming events for ACPH
Similar to ACPH
FAQ
What is the Acacia Pharma share price?
As of Today at 19:54 UTC, shares in Acacia Pharma are trading at €2.21. This share price information is delayed by 15 minutes.
How has the Acacia Pharma share price performed this year?
Shares in Acacia Pharma last closed at €2.21 and the price had moved by +0.23% over the past 365 days. In terms of relative price strength the Acacia Pharma share price has underperformed the FTSE Global All Cap Index by -22.18% over the past year.
What are the analyst and broker recommendations for Acacia Pharma?
The overall consensus recommendation for Acacia Pharma is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Acacia Pharma dividend yield?
Acacia Pharma does not currently pay a dividend.
Does Acacia Pharma pay a dividend?
Acacia Pharma does not currently pay a dividend.
When does Acacia Pharma next pay dividends?
Acacia Pharma does not currently pay a dividend.
How do I buy Acacia Pharma shares?
To buy shares in Acacia Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Acacia Pharma?
As of the previous close price of €2.21, shares in Acacia Pharma had a market capitalisation of €219.87m.
Where are Acacia Pharma shares listed?
Here are the trading details for Acacia Pharma:
- Country of listing: Belgium
- Exchange: BRU
- Ticker Symbol: ACPH
What kind of share is Acacia Pharma?
Based on an overall assessment of its quality, value and momentum Acacia Pharma is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Acacia Pharma share price forecast for 2021?
The analyst consensus target price for shares in Acacia Pharma is €8.01. That is 263.32% above the last closing price of €2.21.
Analysts covering Acacia Pharma currently have a consensus Earnings Per Share (EPS) forecast of -€0.52 for the next financial year.
What is the trend in the Acacia Pharma share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Acacia Pharma. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -33.8%.
As of the last closing price of €2.21, shares in Acacia Pharma were trading -10.75% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Acacia Pharma PE Ratio?
We are not able to find PE ratio data for Acacia Pharma.
Who are the key directors of Acacia Pharma?
Acacia Pharma's management team is headed by:
- Michael Bolinder - CEO
- Gary Gemignani -
- Gabriel Fox -
- Debra Hussain -
- Anne-Marie Elsley -
- Scott Byrd -
- Edward Borkowski -
- John Brown -
Who are the major shareholders of Acacia Pharma?
We do not have data on Acacia Pharma's shareholders